bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
177 hedge funds and large institutions have $310M invested in bluebird bio in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 71 increasing their positions, 41 reducing their positions, and 31 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 41
0.48% more ownership
Funds ownership: 4.1% → 4.58% (+0.48%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 184 → 177 (-7)
12% less call options, than puts
Call options by funds: $3.48M | Put options by funds: $3.97M
23% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 31
32% less capital invested
Capital invested by funds: $457M → $310M (-$147M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$30M |
| 2 |
State Street
Boston,
Massachusetts
|
+$28.6M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$24.8M |
| 4 |
DM
Deerfield Management
New York
|
+$12.4M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$4.51M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.33M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$4.14M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$2.87M |
| 5 |
HF
HRT Financial
New York
|
-$2.51M |
BLUE Hedge Fund Activity: Q1 2023 in Review
177 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q1 2023, worth a combined $310M — down 32% from $457M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of BLUE and 24 opened new positions — a net loss of 7 holders — while 41 trimmed existing stakes and 71 added.
The largest buyer was Tang Capital Management, adding an estimated $30M. The largest seller was Nuveen, cutting an estimated $4.51M.
- 177 institutional investors held bluebird bio (BLUE) as of Q1 2023, down from 184 in Q4 2022.
- Funds reported $310M of bluebird bio stock for Q1 2023, down 32% quarter-over-quarter.
- 24 funds opened new bluebird bio positions in Q1 2023 and 31 closed out, a net change of -7 holders.
- The largest bluebird bio buyer in Q1 2023 was Tang Capital Management, an estimated $30M added.
- The largest bluebird bio seller in Q1 2023 was Nuveen, an estimated $4.51M sold.
Based on aggregated 13F filings for Q1 2023.